Treatment beyond progression: is it moving from belief to evidence?

Oncologist. 2010;15(8):796-8. doi: 10.1634/theoncologist.2010-0137. Epub 2010 Jul 29.

Abstract

This editorial comments on the manuscript of Extra and colleagues in this issue of The Oncologist reporting on the use of trastuzumab for metastatic breast cancer patients.

Publication types

  • Comment
  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease Progression
  • Endpoint Determination
  • Humans
  • Neoplasms / enzymology
  • Neoplasms / pathology*
  • Neoplasms / therapy*
  • Receptor, ErbB-2 / antagonists & inhibitors

Substances

  • Receptor, ErbB-2